Ipamorelin is a synthetic growth hormone releasing peptide that stimulates pulsatile GH secretion from the pituitary gland. Using it correctly requires precise dosing, proper timing, and evaluation by a licensed provider. telos rx does not currently offer ipamorelin, so this guide is educational only.
Ipamorelin is not FDA-approved for any human therapeutic use. All use is subject to medical approval by a licensed provider. This guide covers the protocol steps commonly referenced in clinical and research literature; your provider's instructions take precedence over any general guidance.
Step 1: Understand What Ipamorelin Is — and Is Not
Ipamorelin is a pentapeptide growth hormone releasing peptide (GHRP) that selectively stimulates the pituitary to release GH without meaningfully elevating cortisol, prolactin, or ACTH. This selectivity distinguishes it from earlier GHRPs like GHRP-2 and GHRP-6. A foundational study published in Growth Hormone & IGF Research (1998) confirmed ipamorelin's selective GH-releasing action in animal models, with a clean hormonal profile at standard doses.
Ipamorelin is frequently combined with a growth hormone releasing hormone (GHRH) analogue — such as CJC-1295 — to generate a synergistic GH pulse. It is also compared against secretagogues like MK-677 (an oral option) and sermorelin (a GHRH-class analogue). Which approach is appropriate depends on your goals and a provider's clinical assessment of your baseline.
Step 2: Know That a Provider Evaluation Comes First
Ipamorelin is a compounded medication. It is subject to medical approval by a licensed provider and cannot be legally self-prescribed. Do not adjust dosing, cycle length, or injection frequency without direct provider guidance.
Any legitimate prescription starts with a licensed provider reviewing health history and relevant lab values. Approval is not guaranteed; providers make an independent clinical determination for each patient. Only proceed with the steps below after a licensed provider has reviewed your file and issued a prescription.
Step 3: Know the Standard Dosing Range
The ranges below reflect protocols described in the published literature. Your provider may prescribe a different dose based on your individual presentation, labs, and goals.
| Parameter | Common Range |
|---|---|
| Dose per injection | 100–300 mcg |
| Injections per day | 1–3 |
| Cycle length | 8–16 weeks |
| Administration route | Subcutaneous injection |
| Typical starting dose | 100–200 mcg, once nightly |
Increasing dose beyond the prescribed range does not proportionally increase GH output and may increase the likelihood of side effects without added clinical benefit.
Step 4: Prescription Vials vs. Research Vials
A prescription compounded peptide is generally dispensed by a licensed pharmacy ready to use, prepared at the prescribed dose. There is nothing to mix, no bacteriostatic water to buy, and no dose to calculate, and the label explains how to use and store it.
Many online guides describe a mixing step because unregulated "research" vials ship as a freeze-dried powder. Buyers of those vials have to add a diluent and then work out how much liquid holds their dose, and a small slip at either point changes the amount injected. A prescription removes that step.
- Wash your hands and wipe the vial stopper with an alcohol swab before each dose.
- Store the vial as the label directs, usually refrigerated between 36 and 46°F (2 to 8°C), and use it within the window on the label.
- Discard any vial that appears cloudy, discolored, or contains visible particles, and contact the dispensing pharmacy.
Step 5: Time Your Injections for Maximum Effect
GH is released in pulses. Strategic injection timing avoids competing with periods of natural GH suppression:
- Before sleep: The largest endogenous GH pulse occurs during slow-wave sleep. Injecting 30–60 minutes before bed may amplify this pulse.
- Morning fasted: Insulin suppresses GH secretion. Injecting before eating — in a fasted state — avoids glucose-mediated blunting of the GH response.
- Post-exercise: Exercise produces a natural GH spike. A third injection in the post-workout window (fasted or low-carbohydrate) is used in some multi-dose protocols.
As a general principle, avoid injecting within 2 hours of a high-carbohydrate meal. Elevated blood glucose and insulin significantly reduce the effectiveness of any GH-releasing peptide.
Step 6: Recognize Potential Side Effects
Ipamorelin is associated with a favorable side effect profile relative to exogenous GH, but adverse effects can occur. Commonly reported effects include:
- Injection site reactions: Transient redness, mild swelling, or tenderness at the injection site.
- Headache or lightheadedness: Associated with rapid GH release, particularly at higher doses. Typically resolves within minutes.
- Mild water retention: Edema can occur during the early weeks of a protocol, often resolving as the body adjusts.
- Tingling or numbness: Particularly in the hands and wrists — a known correlate of elevated IGF-1. Usually transient.
- Increased appetite: Less pronounced than with GHRP-6, but reported in some users at higher doses.
Because ipamorelin is not FDA-approved for any human therapeutic use, long-term safety data in humans remains limited. Report any persistent or concerning symptoms to your provider promptly. For a summary of the published evidence base, see the independent review at Examine.com's ipamorelin research page.
Step 7: Monitor Your Response and Follow Up With Your Provider
Effective ipamorelin use involves ongoing monitoring, not a one-time prescription. Key markers typically tracked throughout a protocol include:
- IGF-1: The primary biomarker for GH axis activity. Measured at baseline and mid-cycle to assess response.
- Fasting glucose and insulin: To screen for glucose regulation changes.
- Subjective outcomes: Sleep quality, recovery, body composition trajectory, and energy levels.
Follow-up typically means sharing labs and symptom updates with the prescriber, who reviews them over time. Providers may modify or discontinue a prescription based on follow-up data. Approval at initiation does not guarantee continuation of a protocol.
Frequently Asked Questions
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved for any human therapeutic use. It is available as a compounded medication prepared under federal compounding regulations and is prescribed off-label by licensed providers where clinically appropriate. telos rx does not currently offer ipamorelin.
How long before I see results from ipamorelin?
Improvements in sleep quality are often reported within the first 2–4 weeks. Measurable body composition changes — such as shifts in lean mass and fat distribution — typically appear after 8–12 weeks of consistent protocol adherence. Individual results vary and are not guaranteed.
Can I use ipamorelin without combining it with CJC-1295?
Yes. Ipamorelin functions as a standalone peptide. Combining it with a GHRH analogue like CJC-1295 produces a larger synergistic GH pulse, but many protocols use ipamorelin alone. Your licensed provider will determine the appropriate approach for your clinical picture.
How should I store ipamorelin?
Store it as the label directs, usually refrigerated between 36 and 46°F (2 to 8°C), and use it within the window on the label. A pharmacy-dispensed prescription comes ready to use, while research vials must be mixed and measured by the buyer. Do not freeze it. Protect it from light and temperature extremes.
What time of day should I inject ipamorelin?
The most commonly used timing is 30–60 minutes before sleep, aligned with the body's largest natural GH pulse. Some protocols add a morning fasted injection or a post-exercise dose. Follow your provider's specific instructions for your protocol.
Does ipamorelin raise cortisol or prolactin?
At standard doses, ipamorelin does not significantly elevate cortisol, prolactin, or ACTH — a selectivity profile that distinguishes it from earlier GHRPs. This is one reason ipamorelin has remained a preferred research peptide for GH stimulation studies.
Talk to a provider about your options at telos rx.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.